Aptevo Therapeutics (APVO) Enterprise Value (2016 - 2025)
Aptevo Therapeutics' Enterprise Value history spans 11 years, with the latest figure at -$3.2 million for Q3 2025.
- For Q3 2025, Enterprise Value rose 58.38% year-over-year to -$3.2 million; the TTM value through Sep 2025 reached -$3.2 million, up 58.38%, while the annual FY2024 figure was -$1.2 million, 93.01% up from the prior year.
- Enterprise Value for Q3 2025 was -$3.2 million at Aptevo Therapeutics, up from -$8.1 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1.2 million in Q4 2024 and bottomed at -$62.9 million in Q2 2021.
- The 5-year median for Enterprise Value is -$17.0 million (2023), against an average of -$22.8 million.
- The largest annual shift saw Enterprise Value crashed 564.96% in 2021 before it surged 93.01% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$46.3 million in 2021, then skyrocketed by 53.42% to -$21.6 million in 2022, then rose by 21.63% to -$16.9 million in 2023, then soared by 93.01% to -$1.2 million in 2024, then tumbled by 173.24% to -$3.2 million in 2025.
- Per Business Quant, the three most recent readings for APVO's Enterprise Value are -$3.2 million (Q3 2025), -$8.1 million (Q2 2025), and -$1.3 million (Q1 2025).